A unique T cell subset described as CD4loCD40+ T cells (TCD40) in human type 1 diabetes

Clinical Immunology

Volumn 124, Issue 2, 2007, Pages 138-148

  Waid, Dan M ^a   Wagner, Rebecca J ^b   Putnam, Amy ^c   Vaitaitis, Gisela M ^a   Pennock, Nathan D ^a   Calverley, David C ^a,d   Gottlieb, Peter ^a,b   Wagner Jr , David H ^a  

^a UNIVERSITY OF COLORADO   (United States)

^b UNIVERSITY OF COLORADO DENVER   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Auto reactive T cells; Autoimmunity; CD40; Type 1 diabetes

Indexed keywords

CD40 ANTIGEN; CHEMOKINE RECEPTOR CXCR3; HLA DR3 ANTIGEN; HLA DR4 ANTIGEN;

ARTICLE; CD4+ T LYMPHOCYTE; CELL PROLIFERATION; CONTROLLED STUDY; FEMALE; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; LYMPH NODE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RISK FACTOR; T LYMPHOCYTE;

ADOLESCENT; ADULT; AMINO ACID SEQUENCE; ANTIGENS, CD40; AUTOANTIGENS; CASE-CONTROL STUDIES; CD4-POSITIVE T-LYMPHOCYTES; DIABETES MELLITUS, TYPE 1; DOUBLE-BLIND METHOD; FEMALE; HLA ANTIGENS; HUMANS; MALE; MIDDLE AGED; MOLECULAR SEQUENCE DATA; PLATELET MEMBRANE GLYCOPROTEIN IIB; RECEPTORS, CHEMOKINE; T-LYMPHOCYTE SUBSETS; T-LYMPHOCYTES, REGULATORY;

EID: 34447298600     PISSN: 15216616     EISSN: 15217035     Source Type: Journal    
DOI: 10.1016/j.clim.2007.05.003     Document Type: Article

References (43)

1. Wagner Jr. D.H., Vaitaitis G., Sanderson R., Poulin M., Dobbs C., and Haskins K. Expression of CD40 identifies a unique pathogenic T cell population in type 1 diabetes. Proc. Natl. Acad. Sci. U. S. A. 99 (2002) 3782
2. Vaitaitis G.M., Poulin M., Sanderson R.J., Haskins K.J., and Wagner Jr. D.H. CD40-induced expression of recombination activating gene (RAG) 1 and RAG2: a mechanism for the generation of autoaggressive T cells in the periphery. Cutting Edge, J. Immunol. 170 (2003) 3455
3. + auto-aggressive T cells during insulin-dependent diabetes mellitus. Eur. J. Immunol. 34 (2004) 1488
4. Bach J.F., and Chatenoud L. Tolerance to islet autoantigens in type 1 diabetes. Annu. Rev. Immunol. 19 (2001) 131
5. Kent S.C., Chen Y., Bregoli L., Clemmings S.M., Kenyon N.S., Ricordi C., Hering B.J., and Hafler D.A. Expanded T cells from pancreatic lymph nodes of type 1 diabetic subjects recognize an insulin epitope. Nature 435 (2005) 224
6. Reijonen H., Novak E.J., Kochik S., Heninger A., Liu A.W., Kwok W.W., and Nepom G.T. Detection of GAD65-specific T-cells by major histocompatibility complex class II tetramers in type 1 diabetic patients and at-risk subjects. Diabetes 51 (2002) 1375
7. + T-cells detected by MHC class II tetramers in peripheral blood of type 1 diabetes patients and at-risk subjects. J. Autoimmun. 25 (2005) 235
8. Wagner Jr. D.H., Newell E., Sanderson R., Freed J.H., and Newell M.K. Increased expression of CD40 on thymocytes and peripheral T cells in autoimmunity: a mechanism for acquiring changes in the peripheral T cell receptor repertoire. Int. J. Mol. Med. 4 (1999) 231
9. Gustke C.J., Stein S.H., Hart T.C., Hoffman W.H., Hanes P.J., Russell C.M., Schuster G.S., and Watson S.C. HLA-DR alleles are associated with IDDM, but not with impaired neutrophil chemotaxis in IDDM. J. Dent. Res. 77 (1998) 1497
10. + T cell contact-dependent activation of monocyte interleukin-1 synthesis. Eur. J. Immunol. 24 (1994) 3148
11. Folzenlogen D., Hofer M.F., Leung D.Y., Freed J.H., and Newell M.K. Analysis of CD80 and CD86 expression on peripheral blood B lymphocytes reveals increased expression of CD86 in lupus patients. Clin. Immunol. Immunopathol. 83 (1997) 199
12. Zhang Y., O'Brien B., Trudeau J., Tan R., Santamaria P., and Dutz J.P. In situ beta cell death promotes priming of diabetogenic CD8 T lymphocytes. J. Immunol. 168 (2002) 1466
13. Wong F.S., and Janeway Jr. C.A. The role of CD4 vs. CD8 T cells in IDDM. J. Autoimmun. 13 (1999) 290
14. Wong F.S., Visintin I., Wen L., Flavell R.A., and Janeway Jr. C.A. CD8 T cell clones from young nonobese diabetic (NOD) islets can transfer rapid onset of diabetes in NOD mice in the absence of CD4 cells. J. Exp. Med. 183 (1996) 67
15. + T cell memory. Science 297 (2002) 2060
16. + Tregs. J. Clin. Invest. 115 (2005) 2904
17. Windsor L., Puschendorf M., Allcock R., Scott A., Sayer D., Kucharzak R., Gut I., McCann V., Davis E., Witt C., Christiansen F., and Price P. Does a central MHC gene in linkage disequilibrium with HLA-DRB1*0401 affect susceptibility to type 1 diabetes?. Genes Immun. 6 (2005) 298
18. Sonderstrup G., and McDevitt H.O. DR, DQ, and you: MHC alleles and autoimmunity. J. Clin. Invest. 107 (2001) 795
19. Valdes A.M., Wapelhorst B., Concannon P., Erlich H.A., Thomson G., and Noble J.A. Extended DR3-D6S273-HLA-B haplotypes are associated with increased susceptibility to type 1 diabetes in US Caucasians. Tissue Antigens 65 (2005) 115
20. Barker J.M., Barriga K.J., Yu L., Miao D., Erlich H.A., Norris J.M., Eisenbarth G.S., and Rewers M. Prediction of autoantibody positivity and progression to type 1 diabetes: Diabetes Autoimmunity Study in the Young (DAISY). J. Clin. Endocrinol. Metab. 89 (2004) 3896
21. Viglietta V., Kent S.C., Orban T., and Hafler D.A. GAD65-reactive T cells are activated in patients with autoimmune type 1a diabetes. J. Clin. Invest. 109 (2002) 895
22. Rogers N.J., Jackson I.M., Jordan W.J., Lombardi G., Delikouras A., and Lechler R.I. CD40 can costimulate human memory T cells and favors IL-10 secretion. Eur. J. Immunol. 33 (2003) 1094
23. Christen U., McGavern D.B., Luster A.D., von Herrath M.G., and Oldstone M.B. Among CXCR3 chemokines, IFN-gamma-inducible protein of 10 kDa (CXC chemokine ligand (CXCL) 10) but not monokine induced by IFN-gamma (CXCL9) imprints a pattern for the subsequent development of autoimmune disease. J. Immunol. 171 (2003) 6838
24. Shigihara T., Oikawa Y., Kanazawa Y., Okubo Y., Narumi S., Saruta T., and Shimada A. Significance of serum CXCL10/IP-10 level in type 1 diabetes. J. Autoimmun. 26 (2006) 66
25. Frigerio S., Junt T., Lu B., Gerard C., Zumsteg U., Hollander G.A., and Piali L. Beta cells are responsible for CXCR3-mediated T-cell infiltration in insulitis. Nat. Med. 8 (2002) 1414
26. Yamada S., Oikawa Y., Sakai G., Atsumi Y., Maruyama T., and Shimada A. Expression levels of CXC chemokine receptors 3 are associated with clinical phenotype of type 1 diabetes. Ann. N. Y. Acad. Sci. 1079 (2006) 186
27. Lohmann T., Laue S., Nietzschmann U., Kapellen T.M., Lehmann I., Schroeder S., Paschke R., and Kiess W. Reduced expression of Th1-associated chemokine receptors on peripheral blood lymphocytes at diagnosis of type 1 diabetes. Diabetes 51 (2002) 2474
28. + T lymphocytes primed by myeloid or plasmacytoid dendritic cells. Eur. J. Immunol. 33 (2003) 474
29. Sallusto F., Lanzavecchia A., and Mackay C.R. Chemokines and chemokine receptors in T-cell priming and Th1/Th2-mediated responses. Immunol. Today 19 (1998) 568
30. Sharif S., Arreaza G.A., Zucker P., and Delovitch T.L. Regulatory natural killer T cells protect against spontaneous and recurrent type 1 diabetes. Ann. N. Y. Acad. Sci. 958 (2002) 77
31. Arif S., Tree T.I., Astill T.P., Tremble J.M., Bishop A.J., Dayan C.M., Roep B.O., and Peakman M. Autoreactive T cell responses show proinflammatory polarization in diabetes but a regulatory phenotype in health. J. Clin. Invest. 113 (2004) 451
32. Wong P.K., Quinn J.M., Sims N.A., van Nieuwenhuijze A., Campbell I.K., and Wicks I.P. Interleukin-6 modulates production of T lymphocyte-derived cytokines in antigen-induced arthritis and drives inflammation-induced osteoclastogenesis. Arthritis Rheum. 54 (2006) 158
33. Perry M.G., Richards L., Harbuz M.S., Jessop D.S., and Kirwan J.R. Sequential synovial fluid sampling suggests plasma and synovial fluid IL-6 vary independently in rheumatoid arthritis. Rheumatology (Oxford) (2005)
34. Zwerina J., Redlich K., Schett G., and Smolen J.S. Pathogenesis of rheumatoid arthritis: targeting cytokines. Ann. N. Y. Acad. Sci. 1051 (2005) 716
35. Poulin M., and Haskins K. Induction of diabetes in nonobese diabetic mice by Th2 T cell clones from a TCR transgenic mouse. J. Immunol. 164 (2000) 3072
36. J.D.H. Wagner, In Press. Reshaping the T cel repertoire: TCR editing and TCR revision for Good and for Bad. Clin Immunol.
37. Durinovic-Bello I., Rosinger S., Olson J.A., Congia M., Ahmad R.C., Rickert M., Hampl J., Kalbacher H., Drijfhout J.W., Mellins E.D., Al Dahouk S., Kamradt T., Maeurer M.J., Nhan C., Roep B.O., Boehm B.O., Polychronakos C., Nepom G.T., Karges W., McDevitt H.O., and Sonderstrup G. DRB1*0401-restricted human T cell clone specific for the major proinsulin73-90 epitope expresses a down-regulatory T helper 2 phenotype. Proc. Natl. Acad. Sci. U. S. A. 103 (2006) 11683
38. Lazzeri E., and Romagnani P. CXCR3-binding chemokines: novel multifunctional therapeutic targets. Curr. Drug Targets Immune Endocr. Metabol. Disord. 5 (2005) 109
39. Balashov K.E., Rottman J.B., Weiner H.L., and Hancock W.W. CCR5(+) and CXCR3(+) T cells are increased in multiple sclerosis and their ligands MIP-1alpha and IP-10 are expressed in demyelinating brain lesions. Proc. Natl. Acad. Sci. U. S. A. 96 (1999) 6873
40. Arimilli S., Ferlin W., Solvason N., Deshpande S., Howard M., and Mocci S. Chemokines in autoimmune diseases. Immunol. Rev. 177 (2000) 43
41. Cooper C.J., Turk G.L., Sun M., Farr A.G., and Fink P.J. Cutting edge: TCR revision occurs in germinal centers. J. Immunol. 173 (2004) 6532
42. + T cell tolerance induced by deletion and TCR revision. J. Immunol. 171 (2003) 6290
43. Cooper C.J., Orr M.T., McMahan C.J., and Fink P.J. T cell receptor revision does not solely target recent thymic emigrants. J. Immunol. 171 (2003) 226